Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience

Click to increase image sizeClick to decrease image size

Disclosure statement

SAR and SLG: Kite, a Gilead company: research funding. Iovance Biotherapeutics: research funding. ZIOPHARM Oncology: research funding. JNK: Kite, a Gilead company: research funding and royalties on patents. Bristol Myers Squibb: research funding. Kyverna Therapeutics, Inc.: royalties on patents. JNB: Kyverna Therapeutics, Inc.: scientific advisory committee (unpaid position). No other authors have conflicts of interest.

Author contributions

JNK and SAR designed the clinical trial and patient treatment protocols and reviewed and edited the manuscript. SJS, PHM, and JNB analyzed the patient data and wrote the manuscript. MAA contributed to the Figure and reviewed and edited the manuscript. SLG, JCY, and LM provided patient care and reviewed and edited the manuscript.

Acknowledgments

The authors thank all investigators, research nurses, patient care coordinators, and NIH Clinical Center personnel who assisted in the care of these patients. The authors especially thank the patients and their families.

Additional information

Funding

The research reported here was supported by the Intramural Research Program of the NIH and the National Cancer Institute Center for Cancer Research.